ADMA Biologics, Inc. (ADMA) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of February 28, 2026, ADMA Biologics, Inc. (ADMA) trades at a price-to-earnings ratio of 19.2x, with a stock price of $15.57 and trailing twelve-month earnings per share of $0.86.
The current P/E is 51% below its 5-year average of 39.3x. Over the past five years, ADMA's P/E has ranged from a low of 17.0x to a high of 80.9x, placing the current valuation at the 17th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, ADMA trades at a 19% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, ADMA trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ADMA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Commercial Specialty Pharma peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
UTHRUnited Therapeutics Corporation | $22B | 18.1Lowest | 0.94Best | +13% |
ALKSAlkermes plc | $5B | 21.0 | - | -34% |
ADMAADMA Biologics, Inc. | $4B | 19.2 | - | +723%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $14.66 | $0.86 | 17.0x | -57% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $18.21 | $0.86 | 21.2x | -46% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $19.84 | $0.85 | 23.3x | -41% |
| FY2024 Q4 | $17.15 | $0.82 | 21.0x | -46% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $19.99 | $0.28 | 72.1x | +84% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $11.18 | $0.14 | 80.9x | +106% |
Average P/E for displayed period: 39.3x
See ADMA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ADMA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ADMA vs AGIO
See how ADMA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ADMA stock overvalued or undervalued?
ADMA trades at 19.2x P/E, below its 5-year average of 39.3x. At the 17th percentile of historical range, the stock is priced at a discount to its own history.
How does ADMA's valuation compare to peers?
ADMA Biologics, Inc. P/E of 19.2x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is ADMA's PEG ratio?
ADMA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2025.